Apnimed Secures Up to $150 Million in Debt Financing with HealthCare Royalty Partners to Support Planned AD109 Commercial Launch

Rhea-AI Summary

Apnimed secured a senior secured credit facility of up to $150 million from funds managed by HealthCare Royalty Partners to fund commercial readiness and a planned U.S. launch of AD109 for obstructive sleep apnea.

Apnimed will receive $50 million at closing, a second $50 million upon FDA approval of AD109, and a third $50 million upon a sales milestone. The deal includes a four-year interest-only period (five years if a net sales milestone is met) and a low single-digit synthetic royalty on AD109 net sales. Apnimed expects to submit an NDA for AD109 later this quarter, supported by positive Phase 3 SynAIRgy and LunAIRo results.

Positive

• $150M committed senior secured facility
• $50M initial funding at closing
• NDA submission for AD109 expected later this quarter

Negative

• Synthetic royalty of a low single-digit percentage on AD109 net sales
• Future tranches contingent on FDA approval and sales milestone
• Debt carries an interest-only period and repayment obligations

News Market Reaction – KKR

-0.20%

-0.20% Session close to close

In the Apr 6 session, KKR declined 0.20%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details Apnimed’s up to $150 million senior secured credit facility with HealthCar...

Analysis

This announcement details Apnimed’s up to $150 million senior secured credit facility with HealthCare Royalty Partners, including three $50 million tranches and a four- to five-year interest-only structure. The financing is tied to AD109’s regulatory and commercial path, with an NDA submission expected later this quarter and a low single-digit synthetic royalty on net sales. Investors may watch for FDA review progress, sales milestones, and any follow-on capital needs.

Key Figures

Debt facility size: $150 million Initial tranche: $50 million Approval-linked tranche: $50 million +5 more

8 metrics

Debt facility size $150 million Maximum size of senior secured credit facility with HCRx

Initial tranche $50 million Amount received by Apnimed at closing

Approval-linked tranche $50 million Additional tranche upon FDA approval of AD109

Sales milestone tranche $50 million Third tranche contingent on pre-specified sales milestone

Interest-only period 4 years Base interest-only term of the financing

Extended interest-only 5 years Extended term if specified net sales milestone achieved

Synthetic royalty rate low single-digit percentage Royalty on net sales of AD109 and certain revenues

NDA timing later this quarter Expected timing of AD109 New Drug Application submission

Historical Context

5 past events · Latest: Apr 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 02	Fund closing	Positive	-0.1%	Closed approximately $23B North America private equity fund with strong track record metrics.
Apr 01	Research report	Negative	-1.2%	Retirement outlook study highlighted elevated income anxiety among Gen X vs Boomers.
Mar 31	Acquisition deal	Positive	+2.4%	Agreed to privatize Taiyo Holdings via tender offer at notable premium levels.
Mar 31	Strategic investment	Positive	+2.4%	Japan Post Insurance acquired minority stake in KKR-controlled Hoken Minaoshi Hompo Group.
Mar 25	Portfolio sale	Positive	+1.2%	Agreed sale of CoolIT to Ecolab for $4.75B, generating about 15x equity return.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent KKR headlines with generally positive business developments have mostly seen share price gains, with one notable divergence on the large North America private equity fund close.

Recent Company History

Over the past weeks, KKR reported several significant corporate actions. On Mar 25, it agreed to sell CoolIT to Ecolab for $4.75 billion with about a 15x equity return, and the stock rose 1.21%. On Mar 31, announcements around Taiyo Holdings’ privatization and Japan Post Insurance’s minority stake coincided with a 2.37% move. However, closing the $23 billion North America Fund XIV on Apr 2 aligned with a modest -0.14% reaction.

Key Terms

senior secured credit facility, synthetic royalty, net sales, new drug application (nda), +4 more

8 terms

senior secured credit facility financial

"entered into a senior secured credit facility for up to $150 million"

A senior secured credit facility is a loan or revolving line of credit where lenders have first legal claim on specific company assets (collateral) and the debt ranks above other obligations for repayment. For investors it signals where a lender sits in the repayment pecking order and how much protection creditors have if the company struggles, affecting credit costs, the company’s ability to borrow more, and potential recoveries in a default — like a mortgage taking priority over other claims on a house.

synthetic royalty financial

"Apnimed also agreed to pay a synthetic royalty equal to a low single-digit"

A synthetic royalty is a financial arrangement where one party receives payments that mimic the income from a traditional royalty, like earnings from a patent or natural resource, without owning the underlying asset. It allows companies or investors to replicate the financial benefits of royalties through contractual agreements, often for strategic or tax reasons. For investors, understanding synthetic royalties helps assess how a company generates income and the potential risks involved.

net sales financial

"percentage of net sales of AD109 and certain other specified revenues"

Net sales is the total money a company earns from selling its goods or services after subtracting returns, discounts, and allowances — like a store counting the cash it actually keeps after refunds and coupons. Investors use net sales to gauge true customer demand and the real size of a business’s revenue stream, since it forms the basis for profit margins, growth trends, and comparisons between companies.

new drug application (nda) regulatory

"On track to submit New Drug Application (NDA) for AD109 later this quarter"

A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.

u.s. food and drug administration (fda) regulatory

"if approved by the U.S. Food and Drug Administration (FDA)"

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

phase 3 clinical

"positive results from the pivotal SynAIRgy and LunAIRo Phase 3 trials"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

obstructive sleep apnea (osa) medical

"oral pill for the treatment of Obstructive Sleep Apnea (OSA)"

A sleep disorder where a person repeatedly stops breathing or breathes very shallowly during sleep because the airway partly or fully closes, causing snoring, daytime tiredness, and other health risks. Investors care because it drives demand for medical devices, diagnostics, treatments, and ongoing healthcare costs—similar to a chronic equipment failure in a factory that reduces output and increases maintenance and regulatory oversight, affecting revenue, reimbursement and long‑term market growth.

oral therapies medical

"a pharmaceutical company developing novel oral therapies for obstructive"

Medications designed to be swallowed and absorbed through the digestive system, such as pills, tablets or liquids. For investors, oral therapies often mean larger potential markets, easier patient use and lower delivery costs compared with injected or infused drugs — factors that can speed adoption, simplify manufacturing and affect pricing, reimbursement and competitive dynamics much like a user-friendly app outselling a complex, specialist service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Strengthens balance sheet to support commercial readiness and planned U.S. launch of AD109 oral pill for the treatment of Obstructive Sleep Apnea (OSA)
• On track to submit New Drug Application (NDA) for AD109 later this quarter

CAMBRIDGE, Mass., April 6, 2026 /PRNewswire/ -- Apnimed, Inc., a pharmaceutical company developing novel oral therapies for obstructive sleep apnea (OSA), today announced that it has entered into a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners ("HCRx"). The capital is expected to support commercial readiness activities and the planned U.S. launch of Apnimed's lead product candidate, AD109, if approved by the U.S. Food and Drug Administration (FDA).

Under the terms of the agreement, Apnimed will receive $50 million at closing. An additional $50 million tranche will become available upon FDA approval of AD109, and the company may access a third $50 million tranche upon achievement of a pre-specified sales milestone, subject to customary closing conditions.

The financing includes an interest-only period of four years, which is extended to five years, if Apnimed achieves a specified net sales milestone. Apnimed also agreed to pay a synthetic royalty equal to a low single-digit percentage of net sales of AD109 and certain other specified revenues, subject to customary terms and conditions.

"HCR is a highly respected healthcare investor with deep experience in credit financing, and their investment represents an important validation of our investigational product, AD109 and its commercial potential," said Larry Miller, Chief Executive Officer of Apnimed. "This strategic financing provides significant financial flexibility and supports our continued progress toward the potential U.S. commercialization of AD109, if approved."

"With its focused regulatory and commercial strategy for AD109, a novel oral therapy designed to address the root causes of OSA, we believe Apnimed is uniquely positioned to meaningfully impact the treatment landscape for patients living with this serious disease," said Clarke Futch, Chairman and Chief Executive Officer of HealthCare Royalty Partners. "We look forward to supporting Apnimed's continued growth and mission to bring this innovative treatment option to patients as expeditiously as possible."

Apnimed previously reported positive results from the pivotal SynAIRgy and LunAIRo Phase 3 trials for AD109, which will support the planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration, expected later this quarter.

About HealthCare Royalty

HealthCare Royalty ("HCRx") is a leading royalty acquisition company founded in 2006 that is majority owned by KKR & Co. Inc. (NYSE: KKR). Over two decades, the HCRx team has developed a strong track record of investing in commercial-stage and near-commercial-stage biopharmaceutical assets, committing $7+ billion in over 110 biopharmaceutical products. With offices in New York, Stamford, San Francisco, Boston, London and Miami, HCRx continues to advance biopharmaceutical innovation by providing innovative capital solutions to counterparties. For more information, visit https://www.hcrx.com. HEALTHCARE ROYALTY®, HEALTHCARE ROYALTY PARTNERS® and HCRx® are registered trademarks of HealthCare Royalty Management, LLC.

About AD109

AD109 is designed to be the first pharmacological treatment to improve oxygenation during sleep by directly addressing the neuromuscular root cause of upper airway collapse in people with OSA. It is a first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor (NRI). Their combined pharmacological synergy is designed to target the underlying neuromuscular cause of OSA. AD109 is a once-daily pill taken at bedtime that is designed to lower the complexity of intervention and may help more people benefit from effective, restorative sleep. In a disease characterized by complex and invasive treatment options, AD109 may be a simple solution to help improve oxygenation and health wellbeing for people living with OSA. 

About Obstructive Sleep Apnea 

OSA is a serious, chronic sleep-related breathing disease in which the upper airway repeatedly collapses during sleep, leading to intermittent oxygen deprivation. It is caused by two overlapping mechanisms: neuromuscular dysfunction during sleep and predisposing anatomic abnormalities. OSA affects individuals across all walks of life, impacting both males and females of all age groups, ethnicities, and weight classes, including those with or without obesity. An estimated 80 million people in the United States and one billion people worldwide suffer from OSA. 

An individual with OSA can experience hundreds of sleep apnea events in a single night, each one reducing the blood oxygen levels and negatively impacting cellular functions vital to normal health and function. Failure to effectively treat OSA increases the risk of serious long-term health consequences, including cardiovascular, neurocognitive and cardiometabolic damage and heightened mortality. Yet, many patients diagnosed with OSA remain untreated.

About Apnimed 

Apnimed is a privately held late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. We believe the introduction of simple, once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for people with OSA. We believe that OSA would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment, and help more people get the oxygen and restorative sleep needed to thrive.

Based in Cambridge, Mass., Apnimed is advancing AD109, designed to improve oxygenation in individuals living with OSA. We believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA and Apnimed plans to submit its New Drug Application (NDA) to the U.S. Food and Drug Administration (the FDA) in the second quarter of 2026.

Learn more at apnimed.com or follow us on X and LinkedIn. 

Media Contact: 
media@apnimed.com

Investor Contact:
ir@apnimed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/apnimed-secures-up-to-150-million-in-debt-financing-with-healthcare-royalty-partners-to-support-planned-ad109-commercial-launch-302734406.html

SOURCE Apnimed, Inc.

FAQ

What financing did Apnimed (KKR) secure on April 6, 2026 to support AD109?

Apnimed secured a senior secured credit facility of up to $150 million to support AD109 commercialization. According to the company, $50 million is available at closing, with two additional $50 million tranches tied to FDA approval and a sales milestone.

How much cash will Apnimed (KKR) receive at closing and on approval for AD109?

Apnimed will receive $50 million at closing and another $50 million upon FDA approval. According to the company, a third $50 million is unlockable upon achieving a specified sales milestone, subject to closing conditions.

What are the repayment terms and royalty obligations of the Apnimed (KKR) financing?

The facility includes a four-year interest-only period, extendable to five years if a sales milestone is met, plus a low single-digit synthetic royalty. According to the company, customary terms and conditions apply to interest and royalty payments.

Does the Apnimed (KKR) financing affect the planned NDA timing for AD109?

The financing supports commercial readiness while Apnimed proceeds with its planned NDA submission later this quarter. According to the company, positive Phase 3 SynAIRgy and LunAIRo results will support that NDA filing and launch preparations.

What milestones trigger additional funding under Apnimed's (KKR) $150M facility?

Two triggers unlock additional funding: FDA approval of AD109 and a pre-specified sales milestone for a third tranche. According to the company, each tranche is subject to customary closing conditions before funds are released.